|  |
| --- |
| MC extraordinary web-conference on green deal  |
| Minutes | Webex telconf14 December 202011:00 – 12:30 |

**Participants:**

|  |  |
| --- | --- |
| *By phone:*Ina Andreasen, RB Giorgia De Berardinis, Colgate PalmoliveIan Croft, McBridePilar Espina, AdelmaBernd Glassl, IKWAd Jespers, Diversey (Chairman)Gerard Luijkx, Unilever (Vice-Chairman)Anna Melvas, KoHFEleni Papadimitriou, PGThomas Rauch, IHORob Roggeband, P&GFelix Rustemeyer, Henkel Anna Sass Andersen, KoHBKlaudyna Terlick,RBFrançoise van Tiggelen, DeticEdward Whittle, SC Johnson | *From A.I.S.E.:*Luca ContiSascha Nissen Jan Robinson Giulia SebastioValérie SéjournéMohamed TemsamaniAmelie Weber Susanne Zänker |

1. WELCOME AND Reminder on competition policy

The rules of the Competition law were reminded, and all agreed to adhere.

1. approval of agenda

The agenda was approved.

1. KEY TOPIC: European Green deal: recent developments

 (S.Nissen, M.Temsamani, J.Robinson)

* 1. **Chemical Strategy for Sustainability (CSS) and Zero-pollution (ZP) action plan**

J. Robinson reported from the latest developments ([see slides](https://aise.wall.idloom.com/File/Preview?ID=10588)).

She mentioned a recent event that she attended for DUCC, with the MEP M. Spyraki who is calling for a global level playing field for the European Industry that may be affected by the CSS. Beside DUCC, CEFIC, EEB and ECHA were also attending.

She also referred to the upcoming meeting of the Cross Industry Platform on CSS lead by CEFIC to take place during the afternoon, to define the common priority areas to assess how to best create synergies and alliances. The discussion will also include the CEFIC project for a holistic impact assessment of the CSS to the chemical industry, and the possibility for DU sectors to hook onto the survey with their specific questions. The A.I.S.E. Board had followed the MC recommendation for an in-principle agreement to join in, pending the resources and also to ensure that communication on our findings are exclusively left to A.I.S.E.

The A.I.S.E. CSS/ ZP SG will meet again end of January 2021.

* 1. **Climate Action:** [Refer to presentation](https://aise.wall.idloom.com/File/Preview?ID=10590)

 - Commission communication expected 9 Dec 2020 / Launch of Climate Pact
 (16 December 2020)

The Commission published a communication on the European Climate Pact on the 9 December, see slides where the link is included. One of the proposed action is to collect pledges from individuals and organisations who wish to make their contribution to the fight against climate change. The documents and proposals are being looked at in detail to also identify the role for companies and associations.

 - Update from the Board and Climate TF discussion ([see slides](https://aise.wall.idloom.com/File/Preview?ID=10589))

The Board called in October to shift the A.I.S.E. priority from an B to an A to reiterate the mandate of the Climate TF to look at climate action, addressing production and use phase; upstream to be looked at as well. A matrix for an LCA analysis is being set up to quantify the climate footprint of A.I.S.E.’s product portfolio. The next meeting is beginning of January.

* 1. **Circular Economy (CEAP)**
		1. Substantiation of green claims – Debriefing from December Board

[Refer to presentation](https://aise.wall.idloom.com/File/Preview?ID=10591) which are also including the updates from the last Board discussion.

* + 1. Empowering Consumer in the green transition
		2. Packaging & Packaging Waste Directive

The A.I.S.E. contribution to the Public Consultation is in its last phase, as the submission date is 6 January 2020.

* 1. **Other developments**
		1. Discussion at Commission to move the scientific committees such as SCHER and SCCS to ECHA

The MC was informed that under the Green Deal it is being proposed to move 2 scientific committees currently operating under the Commission DG SANTE to ECHA, namely SCCS and SCHER (see below)[[1]](#footnote-2). The reason mentioned is that this would allow to resource better both committees and that ECHA is with its mandate for being a scientific agency a “better” body to host them.

Discussion at CEFIC, Cosmetics Europe level and other associations has started to assess the impact this move could potentially have for industry. Most of the associations were a bit sceptical about the wins for industry, however also feared that whatever industry may say could be misperceived as coming from industry. It would probably make more sense to firstly relook again on the mandate, the tasks and opportunities before issuing an opinion.

***ACTION:***

***- Provide feedback to A.I.S.E. on your views (MC)***

* 1. **Digitalisation**

The members of the MC were informed about the selection of an agency to support A.I.S.E. in the development of IT solutions for the digitalisation of products information ([see slides](https://aise.wall.idloom.com/File/Preview?ID=10592)). Out of the 3 agencies ATRIFY had been retained. In the slides the milestones and mandate are presented. The estimated costs are around €40K, which is in the forecasted budget. The MC approved this choice and the next steps of the project carried out by the Digitalisation TF.

Doc. name: 2020-12-14 MC Minutes Extraordinary webconference on Green Deal A.I.S.E., 16 December 2020

1. The Scientific Committee for Consumer Safety under DG SANTE/ HEALTH provides Opinions on health and safety risks (chemical, biological, mechanical and other physical risks) of non-food consumer products (e.g. cosmetic products and their ingredients, toys, textiles, clothing, personal care and household products) and services.

The Scientific Committee on Health, Environmental and Emerging Risks (SCHEER), on request of Commission services, provides Opinions on questions concerning health, environmental and emerging risks.
In particular, the Committee provides Opinions on questions concerning emerging or newly identified health and environmental risks and on broad, complex or multidisciplinary issues that require a comprehensive assessment of risks to consumer safety or public health and related issues not covered by other European Union risk assessment bodies (such as: antimicrobial resistance; new technologies such as nanotechnologies; medical devices including those incorporating substances of animal and/or human origin; tissue engineering; blood products; fertility reduction; the interaction, synergic effects and cumulative effects of risk factors and methodologies for assessing new risks. [↑](#footnote-ref-2)